Long term evaluation of 5mg zoledronic acid in women with osteoporosis

• Research type

  Research Study

• Full title

  A three year multicentre, double-blind, randomised, placebo-controlled extention to CZOL446H2301 E1 to evaluate the efficacy and long term safety of 6 and 9 years zoledronic acid treatment in post-menopausal women with osteoporosis.

• Contact name

  Femi Adekunle

• Contact email

  femi.adekunle@novartis.com

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2007-005383-27

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  08/H0502/88

• Date of REC Opinion

  26 Nov 2008

• REC opinion

  Further Information Favourable Opinion